April 28, 2023 by admin aurigene AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro
April 28, 2023 by admin aurigene PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
April 28, 2023 by admin aurigene Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
April 28, 2023 by admin aurigene Orally Bioavailable CBP and p300 Selective Degraders for the Treatment of AR- and ER- dependent Cancers
April 28, 2023 by admin aurigene Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)
April 27, 2023 by admin aurigene In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
April 27, 2023 by admin aurigene Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
